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Abstract
This article uses data from Thomson Reuters Web of Science to map and analyse the scientific landscape for synthetic
biology. The article draws on recent advances in data visualisation and analytics with the aim of informing upcoming
international policy debates on the governance of synthetic biology by the Subsidiary Body on Scientific, Technical and
Technological Advice (SBSTTA) of the United Nations Convention on Biological Diversity. We use mapping techniques to
identify how synthetic biology can best be understood and the range of institutions, researchers and funding agencies
involved. Debates under the Convention are likely to focus on a possible moratorium on the field release of synthetic
organisms, cells or genomes. Based on the empirical evidence we propose that guidance could be provided to funding
agencies to respect the letter and spirit of the Convention on Biological Diversity in making research investments. Building
on the recommendations of the United States Presidential Commission for the Study of Bioethical Issues we demonstrate
that it is possible to promote independent and transparent monitoring of developments in synthetic biology using modern
information tools. In particular, public and policy understanding and engagement with synthetic biology can be enhanced
through the use of online interactive tools. As a step forward in this process we make existing data on the scientific
literature on synthetic biology available in an online interactive workbook so that researchers, policy makers and civil society
can explore the data and draw conclusions for themselves.
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Introduction
Synthetic biology is a growing focus of scientific and public
policy attention with respect to safety [1–3], security [4,5], ethics
[6–8], intellectual property [9–12] and the potential benefits or
negative impacts of this emerging field. Pioneering work by NGOs
such as the ETC Group and headlines announcing the creation of
artificial life have increasingly brought policy attention to bear on
synthetic biology [13]. In April of 2012 the Subsidiary Body on
Scientific, Technical and Technological Advice (SBSTTA) of the
United Nations Convention on Biological Diversity will consider
the potential implications of synthetic biology as a new and
emerging issue. Recommendations from SBSTTA will then go
forward to the Eleventh meeting of the governing Conference of
the Parties (COP11) in India in October 2012 for a decision.
Parties to the Convention on Biological Diversity will be
particularly interested in the potential implications of synthetic
biology for the three objectives of the convention: the conservation
of biodiversity; the sustainable use of biodiversity, and; the fair and
equitable sharing of benefits arising from the utilization of genetic
resources. SBSTTA and the Parties to the Convention are likely to
focus on the potential implications of the field release of synthetic
organisms, cells or genomes into the environment for biodiversity
in light of the objectives of the Convention and the precautionary
approach (decision X/13 para. 4).
This article aims to inform upcoming debates on the
governance of synthetic biology by establishing a baseline for
mapping the core of the scientific landscape for synthetic biology.
We build on two recent advances in visualisation and interaction
with scientific information. The first is visualisations of networks of
words, organizations, authors and funding bodies using the open
source network mapping tool, Gephi. The second is the use of
Tableau analytics software to provide interactive visualisation of
information on publications about synthetic biology from
Thomson Reuters Web of Science.
The effect of these approaches is to improve the overall
transparency of synthetic biology to researchers, policy-makers
and civil society interested in the emergence of synthetic biology.
The growing availability of digital data and analytical tools
means that the critical links between data and analysis in social
scientific contributions to evidence based debates can be
maintained and presented in new ways. The emergence of these
tools opens up data to allow researchers, policy makers and civil
society to explore data for themselves, to raise their own
questions and draw their own conclusions. The data in this
article is available as an interactive Tableau workbook in
Workbook S1 for use with free Tableau Reader software and
online through the Synthetic Biology Scientific Landscape
Tableau Public workbook (Legends S1).
Methods
In approaching a new and emerging area of science and
technology within the scientific literature a variety of search
strategies may be used with Thomson Reuters or other publication
databases. The choices made in the development of search
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searches of the Thomson Reuters Web of Knowledge capture a wide
range of results across disciplines and publication sources but are
very limited in terms of data fields for analysis. In contrast,
Thomson Reuters Web of Science provides a narrower spectrum of
results from three major scientific indexes and conference
proceedings but includes all major data fields for analysis. We
selected Web of Science because of the large range of fields available
for text mining and analysis using software tools such as Vantage
Point from Search Technology Inc. All databases suffer from lag
times between the publication of articles and their appearance in
databases.
The second important methodological issue is the use of search
terms. We engaged in experimentation with a range of search
terms using corpus linguistics approaches and Natural Language
Processing to identify individual words and phrases of relevance
from samples of articles from Web of Science and reports on
synthetic biology. This revealed that, in the absence of a controlled
vocabulary, the terms used in synthetic biology such as
biotechnology or protein engineering are rapidly swamped by
uses of the same terms in other research areas. While it is tempting
to use ever more refined terms we came to the conclusion that
synthetic biology is a self-defining community of researchers from
a variety of disciplines who are articulating themselves around the
term synthetic biology and related terms such as synthetic
genomics. For this reason a simple search strategy focusing on
‘‘synthetic biology’’, ‘‘synthetic genomics’’, ‘‘synthetic genome’’
and ‘‘synthetic genomes’’ was used to capture the core landscape.
Other important contributions to the field are captured through
analysis of cited literature and exploration of the landscape of
researchers citing work in synthetic biology within their publica-
tions (below).
Searches were conducted using the topic field in Web of Science
which encompasses the title, abstract, author keywords and terms
appearing in the title of cited literature (keywords plus). The results
were then imported into Vantage Point software from Search
Technology Inc. for text mining and processing of geographical,
institutional and funding data fields. Publications citing this core
landscape were also selected in Web of Science to exclude self-
citations, deduplicated and processed in Vantage Point. The
processed data was then geocoded using Yahoo Place Finder and
exported for visualisation and geographical mapping in Tableau
Desktop and Gephi network mapping software. Data was
prepared for display in Tableau Public by splitting relevant fields
to extract values (i.e. country names). Gephi visualisations
deployed the Fruchterman-Reingold and Force Atlas algorithms
with nodes manually adjusted to ensure label clarity. The data
presented in this article is limited to the literature available in Web
of Science at the time searches were conducted in early January
2012. Data on literature citing the core landscape for synthetic
biology is limited to the 5,995 deduplicated citing publications
available in Web of Science at the time of search.
Results
The Rise of Synthetic Biology
As of January 2012 a total of 1,255 publications were listed in
Web of Science for synthetic biology and synthetic genomics in the
period to the end of December 2011 (Figure 1). These results
include publications and conference proceedings produced by
researchers active in the development of synthetic biology and
work by social scientists and others concerned with understanding
the implications of synthetic biology. This data can be explored in
Workbook S1 and online through the Synthetic Biology Scientific
Landscape.
Viewed historically, references to synthetic biology appeared
sporadically in the literature in the early 1980s and 1990s [14–18].
These early works included recognition of the historical legacy of
Leduc’s (1912) La Biologie Synthe ´tique [17] while work by Krimsky in
1982 anticipated much of the recent debates on the social, ethical
and economic implications of synthetic biology [15].
Following this brief flurry the record largely fell silent with the
exception of work in relation to rescuing synthetic genomic RNA
analogs from the rabies virus by Conzelmann et al and on the L-
protein of rift valley virus and the transcription of synthetic
genome-like RNA molecules by Bouloy et al during the mid-1990s
[19,20]. In the year 2000 Rawls featured work by Eric Kool and
declared the ‘‘debut’’ of synthetic biology [21–23]. However, it
was only in 2007 that the number of publications, excluding
conference proceedings and news items, exceeded 100 records. A
significant proportion of the literature takes the form of review
articles with a provisional total of 62 review articles against 207
articles in 2011 (Figure 1). This profile of review against research
articles suggests an emerging field. Compared with the emergence
of nanotechnology, which records a basic 15,924 publications in
Web of Science for the same period, synthetic biology remains small
scale.
Defining or characterising synthetic biology has become a
significant focus of discussion among researchers [24–30]. Three
characterisations of synthetic biology provide an insight into these
debates. Benner and Sismour identify two broad classes of
synthetic biologists [25]. The first class focus on assembling non-
natural or synthetic components to create chemical systems that
support Darwinian or biological evolution. The second class are
informed by engineering and focus on extracting interchangeable
parts from living systems to create construction units and devices
that may or may not be analogous with existing biological systems
(Benner and Sismour 2005: 553) Both classes focus on the
chemical synthesis of biological components ranging from gene
circuits to entire genomes. However, the first class is concerned
with understanding ‘natural’ biology while the latter focuses on
engineering.
Endy subdivides synthetic biologists into four main groups:
biologists, chemists, ‘re-writers’ and engineers [26]. For biologists,
synthetic biology provides a means to understand natural
biological systems. For chemists it is an extension of synthetic
chemistry leading to the development of novel molecules and
advancing research on the origin of life. For ‘re-writers’ synthetic
biology offers the promise of optimising biological systems
including ‘refactoring’ existing genomes [30]. Finally, for engineers
biology is classified as a ‘technology’ that requires ‘‘the
development of foundational technologies that make the design
and construction of engineered biological systems easier’’ (Endy
2005: 449).
De Lorenzo and Danchin describe synthetic biology as an
‘‘inclusive theoretical and technical framework in which to
approach biological systems with the conceptual tools and
language imported from electrical circuitry and mechanical
manufacturing’’ to pursue ‘‘the rational combination of standard-
ised biological parts that are decoupled from their natural context’’
[31]. From their perspective ‘‘The fundamental idea behind
synthetic biology is that any biological system can be regarded as a
combination of individual functional elements - not unlike those
found in man-made devices. These can therefore be described as a
limited number of parts that can be combined in novel
configurations to modify existing properties or to create new
ones’’ (De Lorenzo and Danchin 2008: 822).
Synthetic Biology Mapping
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calls for independent evaluation and monitoring of this field,
notably by the 2010 report of the United States Presidential
Commission for the Study of Bioethical Issues [8]. Scientometrics
methods can contribute to such assessments by focusing on basic
questions of who, what and where in an empirically rigorous
manner. We turn first to the exploration of the language used in
synthetic biology to describe this field.
The Language of Synthetic Biology
Scientometrics approaches typically use key words and phrases
to explore emerging areas of science [32,33]. A total of 36,262
individual words and phrases from the titles, abstracts and author
key words of publications were available for analysis from our
dataset of 1,255 publications. These terms were then reduced to
24,023 multi-word phrases and composite terms (i.e. biotechnol-
ogy, bionanotechnology) to focus on meaningful concepts and
categories. The terms were then grouped using word stemming to
capture variations of leading terms i.e. biological systems AND
artificial biological systems or metabolic engineering AND
metabolic pathway engineering. This method revealed that 356
terms capture 99% of records on synthetic biology. As we might
expect, the top unifying term is synthetic biology. When synthetic
biology was excluded the remaining 355 terms captured 88% of
records providing sufficient accuracy for representation of the
data. The 355 terms were then placed in a co-occurrence matrix
that provides a quantitative measure of the number of records for
each term (nodes) and the strength of connections between terms
(edges). These relationships were then visualised using the open
source Gephi network analysis software (Figure 2).
Figure 2 reveals that synthetic biology is concerned with
biological systems using approaches from systems biology directed
to biotechnology that involves gene expression, gene networks,
metabolic engineering and genetic circuits, synthetic genes and
synthetic networks. As we move from central terms to the outer
periphery of the network less frequent terms such as biosafety,
bioethics, and intellectual property emerge to reveal the wider
spectrum of issues revolving around the core of synthetic biology.
Figure 3 narrows the focus to the top ranking phrases and
composite terms in more than 20 records across the dataset. In
considering these results it may be tempting to widen the search
criteria for synthetic biology to include additional top occurring
key terms to enhance data capture. For example, synthetic
biology is strongly associated with systems biology, protein
engineering, genetic engineering and nanotechnology. However,
synthetic biology would immediately be swamped by the results
from these much larger fields. In practice, synthetic biology is
being constructed from a combination of convergences and
overlaps with other areas of science and technology, some of
which, such as metabolic engineering, are new and emerging
areas of research.
Figure 1. Publication Trends. Data from Web of Science topic search for synthetic biology or synthetic genomics or synthetic genome or synthetic
genomes in January 2012. Data for recent years may be partial due to lag times. This data can be explored in Workbook S1.
doi:10.1371/journal.pone.0034368.g001
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improved by removing dominant terms to expose underlying
networks. This approach revealed the prominence of relations
between genetic circuits, gene networks, synthetic genes,
synthetic systems and gene regulatory networks [34,35]. Viewed
from this perspective synthetic biology is being constructed from
a core of work around genetic circuits and networks. Much
attention has understandably focused on the potential implica-
tions of synthetic cells, genomes and organisms. However, the
creation of synthetic circuits, synthetic genes, and synthetic gene
networks may eventually be more likely to find routine
expression in organisms and make their way into the wider
environment.
It is also important to note the incipient diversification of
synthetic biology. This is apparent in the case of mammalian
synthetic biology [36], cell free synthetic biology [37] and chemical
synthetic biology [38]. Genome engineering [39] can be classified
alongside genome-scale synthetic biology [40] and work in
synthetic genomics to create synthetic genomes as popularised
by the J. Craig Venter Institute. Other emerging variants of
synthetic biology include in-vitro synthetic biology [41], RNA
synthetic biology [42], cyanobacterial synthetic biology [43], plant
synthetic biology [44] and nano-enabled synthetic biology [45].
While low in frequency, these modules or flavours of synthetic
biology suggest the diversification and potential fragmentation of
the field. This is important for policy debates because the longer
term implication is that synthetic biology may cease to be a
‘unitary’ object for policy action and become multiple in
applications to particular organisms or the components of
organisms.
Viewed purely from the perspective of key terms, synthetic
biology emerges as a research mobilisation around the term
‘‘synthetic biology’’ and, to a lesser extent, ‘‘synthetic genomics’’
that draws on methods, techniques and technologies from a
wider range of established and emergent research areas. That is,
synthetic biology is a rallying flag around which researchers are
articulating themselves focusing on genetic circuits, networks,
pathways and parts and extending to minimal cells, genome
transplantation, synthetic genomes and whole genome engineer-
ing. Synthetic biology draws on a variety of techniques from
systems biology, metabolic engineering, protein engineering and
genetic engineering but cannot simply be reduced to these
fields. Even as synthetic biology emerges as a rallying flag
around which researchers are articulating themselves it is also
diversifying and, at least potentially, fragmenting into specialist
areas focusing on particular approaches and classes of organism.
Figure 2. Key Terms Network. A Fruchterman-Reingold representation in Gephi of the top 356 aggregated terms of 36,262 terms within Web of
Science literature for synthetic biology based on titles, abstracts and author keywords following stemming. Node size is based on the number of
records. Node positions have been adjusted to clarify labels.
doi:10.1371/journal.pone.0034368.g002
Synthetic Biology Mapping
PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e34368As we will see below in exploring the citing landscape the
impacts of synthetic biology are also being disseminated and
picked up in multiple other fields.
Networks and Impacts
In total 40 countries are involved in the core landscape for
research on synthetic biology. Figure 4 displays the rankings and
locations of these countries and organizations. This data can be
explored in Workbook S1 and online through the Synthetic
Biology Scientific Landscape. Web of Science data reveals that
synthetic biology is dominated by the United States followed by
the UK, Germany, France and Switzerland. Emerging major
economies, notably China, Brazil, and India, along with Mexico,
Argentina, South Africa and Singapore are also appearing in the
core scientific landscape.
The emergence of networks of countries reflects the underlying
growth of international collaborative research networks between
institutions and research groups. Mapping of institutions and
organizations revealed 682 organizations with offices in various
locations around the world. Figure 5 provides a visualisation of the
network of organizations with three or more records in Web of
Science data.
In terms of the volume of publications network mapping
reveals the prominence of the University of California at
Berkeley, the Swiss Federal Institute of Technology (ETH),
Harvard and MIT. The data does not discriminate by discipline
with the social sciences represented in work at Berkeley, Exeter
and Edinburgh while law is represented in work at Duke
University [7,10,46,47].
In practical and policy terms, this data informs us that any
regulatory measures that apply to synthetic biology will primarily
be targeted at the 682 organizations in 40 countries within this
network and any new organizations and countries that subse-
quently join the network. As we will see below, research results in
this field are increasingly being picked up by other researchers
resulting in the expansion of the number of countries and
Figure 3. Top Terms. A Fruchterman-Reingold representation in Gephi of the top aggregated terms for synthetic biology within Web of Science
based on titles, abstracts and author keywords appearing in more than 20 or more records following stemming. Node size is based on the number of
records. Node positions have been adjusted to clarify labels.
doi:10.1371/journal.pone.0034368.g003
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biology. Mapping of the scientific literature provides a basis for
engaging in dialogue with the spectrum of researchers and
institutions engaged in research on synthetic biology and for
monitoring synthetic biology over the long term using empirical
evidence.
In practice, inter-institutional collaborations are embodied in
individual researchers and research groups. In total, 2,934 authors
were identified in the available data from Web of Science for the core
landscape. Network mapping in Gephi using the modularity class
algorithm revealed 527 distinct research clusters or modules that
make up the primary human resources for synthetic biology
(Figure 6) [48]. Ranking authors purely by the number of
publications revealed the leading authors to be Fussenegger [49],
Benner [25], Keasling [50], Weber [51], Chen [52], Collins [24],
Silver [53], Weiss [54], Stano [55] and Zhang [56]. The details of
the network come into greater focus in Figure 7 that ranks all
authors with 5 or more publications within the data. This data
includes one social scientist [46] to capture the wider network of
those working on and writing about synthetic biology.
The citation of articles within the wider scientific literature
can provide important insights into research that is shaping an
emerging field and into the impacts of research in a particular
field. Researchers themselves are familiar with citation scores as
an indicator of prestige and they can be important for career
progression in some disciplines. However, citation scores need to
be approached with considerable caution. Citation scores are
heavily biased towards journal publications and publication and
citation practices vary significantly across disciplines such as
biology, computer science, mathematics and engineering [57].
This produces problems in assessing the importance of literature
in the case of interdisciplinary research [58]. Furthermore,
access to citation data may be limited and lacking in
transparency.
Taking these difficulties into account we avoid a ‘top cited’ style
analysis and seek to illuminate the scientific landscape for synthetic
biology in two ways. First, by examining the literature actually
cited by researchers inside the core landscape. Second, by
exploring the wider landscape of literature citing the core
landscape.
The literature cited by participants in a particular research
community provides important insights into research that is
shaping a field. In the case of the core landscape approximately
25,567 authors appear in 37,217 cited references. Unfortunately,
cited references are only available in raw form i.e. Elowitz MB,
2000, NATURE, V403, P335. This is compounded by a
requirement to retrieve cited references individually in Web of
Science. As such, it is not presently realistic to fully map and explore
the cited literature within synthetic biology.
Figure 4. Country Rankings and Organization Distribution Map. The figure ranks countries on the number of authors from a country
appearing in publications in Web of Science linked to geocoded organizational information on their global distribution. Country rankings are base on
data for 1160 records of 1255 records. This data can be explored in Workbook S1.
doi:10.1371/journal.pone.0034368.g004
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Figure 8 provides a summary of the top 30 references cited inside
the core landscape. This data is accessible in Workbook S1 and
online through the Synthetic Biology Scientific Landscape. The
top 5 publications cited inside this community are work by Elowitz
[34] on transcriptional regulation, Gardner [59] on a toggle switch
in E. coli, Gibson et. al [60] on the complete chemical synthesis of
the Mycoplasma genitalium genome, Endy [26] on engineering
biology and Benner and Sismour [25] on synthetic biology. This
data can also be explored for all authors with five or more citations
in the core landscape in Workbook S1 and online through the
Synthetic Biology Scientific Landscape. Future research could
usefully focus on exploring the cited references to examine other
important articles in this field. The data presented here is a first
step in that process.
An insight into the wider impacts of existing research in
synthetic biology is provided by the literature citing publications in
the core landscape. Data on citing publications from the core
landscape was generated using the Citation Report function within
Web of Science. After excluding self-citations and publications in the
core dataset we identified 5,955 distinct citing publications
available in Web of Science. Trends within this wider landscape
can be explored in Workbook S1 and online through the Synthetic
Biology Scientific Landscape.
The citing literature reveals an expanded landscape involving
78 countries, approximately 3,000 organizations, and an estimated
19,751 researchers. In total 1,153 of the 2,934 researchers working
on synthetic biology are present in this landscape and dominate
the publication rankings. Of particular importance within this
landscape, in terms of the number of publications, is work by
Keasling on biofuels [61], Kell on systems biology and the
reconstruction of a yeast metabolic network [62], Baric in relation
to the GII.4 norovirus and related work on the SARS virus [63],
work by Conzelmann on the rabies virus and gene therapy [64],
Figure 5. Organization Network. This network map shows all author organizations with more than three publication records in Web of Science for
the core landscape for synthetic biology. Where available this network map distinguishes organizations by locations (i.e. ETH) to distinguish groups.
This is a Fruchterman-Reingold algorithm network representation in Gephi. The original dense representation was expanded and nodes were
manually adjusted to prevent label overlaps and reduce irrelevant node to edge intersections.
doi:10.1371/journal.pone.0034368.g005
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in areas such as antibiotic production by microorganisms [66].
The citing landscape also reveals other authors working outside
the community of researchers writing on synthetic biology that
demonstrates both the impact and diversification of the influence
of this field. Notable here is work by Katz on biocomputing
[67,68], Dorrestein on the biosynthetic origin of natural products
from marine microorganisms and on multiplex sequencing of
peptide antibiotics [69,70], along with work by Flick on reverse
genetics of negative stranded RNA viruses including research on
Crimean-Congo hemorrhagic fever virus and Rift Valley fever
virus [71–73]. Looking beyond work directed towards potential
applications, research by Dunn focusing on metabolomics and
mass spectrometry provides a reminder of the importance of
methodological development [74,75].
When viewed from the perspective of the language a defining
characteristic of the citing landscape is the absence of references to
synthetic biology, synthetic genomics and synthetic genomes. In
the absence of such unifying terms, the citing landscape is diffuse
and characterised by low frequency terms relative to the size of the
landscape. However, at the apex of this landscape we find
concentrations in work on E. coli by researchers in synthetic
biology such as Collins [76], along with the prominence of terms
such as gene expression [77], systems biology [78] and metabolic
engineering [79].
Figure 6. Author Network. This network map shows the relationships between 527 clusters of authors with publications on synthetic biology in
Web of Science. Node size is based on the number of publications for a given author.
doi:10.1371/journal.pone.0034368.g006
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knowledge transfer between countries and the emergence of
research groups informed by work in synthetic biology. The citing
landscape encompasses researchers from 78 countries. What is
immediately apparent is that countries such as China have risen
from 10
th place in the core landscape to 4
th place and India has
risen from 18
th to 16
th place while Brazil has also risen in the
rankings. What is less apparent is that researchers from the Africa
region are also beginning to appear in the literature. Examples of
this development include Egypt for chemoenzymatic and micro-
bial dynamic kinetic resolutions [80], Ghana on the SARS
coronavirus in bats [81], Nigeria in the case of an ethnobotanical
survey and cytotoxicity testing in plants for potential cancer
treatments [82] and South Africa in research on synthetic
promoters and genetic control through cis engineering [83]. Data
by countries within the citing landscape can be explored in
Workbook S1 and online through the Synthetic Biology Scientific
Landscape.
We are also witnessing the influence of research in synthetic
biology within other fields. In the case of the journal literature, a
quantitative insight into this influence is provided by comparing
Thomson Reuters Web of Science journal subject categories from the
core and the citing landscape (Figure 9). Figure 9 makes clear that
the core of synthetic biology is strongly situated in Biochemistry &
Molecular Biology, followed by Biotechnology & Applied
Microbiology and the interdisciplinary Science & Technology
category. In the citing landscape these categories are reinforced
and shift in importance notably through the influence of synthetic
biology in chemistry. The impacts of synthetic biology are also
observed in the emergence of publications in Virology, Environ-
mental Sciences and Ecology, for subjects such as bioremediation,
and Immunology focusing on areas such as antibiotics, biofilms
and vaccine. Data on journal subject categories for the citing
landscape can be explored in Workbook S1 and online through
the Synthetic Biology Scientific Landscape. Future work in
exploring the emerging scientific landscape for synthetic biology
could build upon recent efforts to map the structure of the
scientific literature using journal subject categories and situate
synthetic biology within this structure [84–86].
The preceding analysis of the emerging networks and impacts of
synthetic biology within the scientific literature has demonstrated
the increasing internationalisation of synthetic biology and its
dissemination across a range of disciplines and research areas. We
now turn to analysis of the network of funding organizations
involved in supporting the core landscape for synthetic biology.
Funding
One of the potential opportunities to introduce appropriate
governance measures is provided by focusing on the institutions
and organizations that fund synthetic biology. Until recently, data
on funding for scientific research was largely obscured in
publication data. Web of Science now includes limited information
Figure 7. Main Authors. This network map shows the network of authors with five or more publications on synthetic biology in Web of Science.
Node size is based on the number of publications for a given author. Node position has been manually adjusted from Figure 5 to clarify labels.
doi:10.1371/journal.pone.0034368.g007
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records representing 44% of records in our dataset published from
2007. Furthermore, data is restricted to information in Web of
Science, lacks standards of description, and does not provide an
insight into the size of awards. However, it is possible to gain a
partial insight into the nature of funding organizations and
emerging networks of funding organizations. After cleaning the
raw data we identified approximately 530 organizations as funding
sources for synthetic biology. Figure 10 provides a visualisation of
the top funding organizations that have supported research
appearing in three or more publications in Web of Science.
Funding is dominated by the National Institutes of Health
(NIH) and the National Science Foundation (NSF) in the United
States and the European Union Framework programme, followed
by the US Department of Energy, the combined agencies of the
US Department of Defense, the Biotechnology and Biological
Sciences Research Council in the UK (BBSRC), the Human
Frontier Science Foundation (HPSF), and the Swiss National
Science Foundation. The Human Frontier Science Program based
in Strasbourg is an international programme established by
Australia, Canada, France, Germany, India, Italy, Japan, South
Korea, Norway, New Zealand, Switzerland, the UK, the
European Union and the United States. The UK would rise in
the rankings measured on publications if its sister organizations
(the Engineering and Physical Sciences Research Council or
EPSRC) and the combined Research Councils UK were
aggregated.
The NIH has funded notable research on synthetic gene
oscillators [87], an ER mitochondria screening tethering complex
using a synthetic biology screen [88], work on synthetic genetic
networks [89] and development of the proposed second wave of
synthetic biology in moving from modules to systems [27]. The
National Science Foundation has funded research focusing on
metabolic engineering for biofuel production [90–93], a synthetic
platform organism for biotechnological applications [94] and
biodegradation pathways [95]. European Union research funding
has supported work on bistability and epigenetic inheritance and
bet hedging in bacteria [96], a yeast synthetic network for assessing
the outcomes of reverse engineering and modelling [97] and
bioremediation [98]. The US Department of Energy, as is well
known from the work of the J. Craig Venter Institute, has been
funding research on biofuels [91,99] along with work on a
synchronized genetic clock for engineering genetic circuits [100]
and whole genome engineering [39]. The United States
Department of Defense, through the Defense Advanced Research
Projects Agency (DARPA), the Office of Naval Research, the Air
Force and the Army, emerges as an important co-funder of
research with other agencies in areas such as bacterial quorum
sensing with respect to biofilms and disease [27,87,101].
Funding by the Swiss National Science Foundation appears to
be more targeted towards biopharmaceutical applications and
work relating to mammals [36,51,102–104]. This highlights that
research funders may begin to focus on distinctive emerging
flavours of synthetic biology. In the UK the BBSRC has funded
work reviewing synthetic biology [105] has served as a co-funder
for work on bistability and epigenetics [96], designing and
encoding models for synthetic biology and engineering protein
assemblies [106,107].
Companies are represented in the data principally through
DuPont in work on genetic circuits [108,109] and renewable
Figure 8. Key Articles in the Core Landscape. This figure shows the main articles cited by other authors inside the core landscape for synthetic
biology. Data is based on counts of citations in the cited literature field of publications in the core landscape. The data does not refer to total citations
for an author or article within the wider scientific literature. This data can be explored in Workbook S1.
doi:10.1371/journal.pone.0034368.g008
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has provided research funding for software and bioinformatics
related research and teaching in these fields [111,112] while IBM
has contributed to work in metabolic engineering [113]. Math-
works, a US company specialising in mathematical computing
software, also emerges as a sponsor of work on gene circuits [114].
Specialist synthetic biology companies such as LS9 emerge as
sponsors of work on microbial fuels [115] as well as the well known
work of Synthetic Genomics through the J. Craig Venter Institute.
Large pharmaceutical companies are represented by Pfizer in
research on PCR-less library mutagenesis [116] and Roche in the
development of the SynBioWave software suite [117]. Looking
outside this data Novartis is present as a funder of research
through work on vaccine development that links to collaborations
with the J. Craig Venter Institute and Synthetic Genomics [118].
Data by funding organization can be explored in Workbook S1
and online through the Synthetic Biology Scientific Landscape.
This type of information is rarely made visible and funding
networks may not be visible to the agencies engaged in supporting
research. We would emphasise that data on the funding network is
limited to 44% of available records and further work is desirable to
standardise funding data in future research. Furthermore, this data
is unlikely to fully or adequately reflect private sector involvement.
A fuller picture will be generated by ongoing work to map the
patent landscape. However, the predominance of organizations
funded by taxpayers within the scientific literature provides
important potential levers for policy makers under the Convention
on Biological Diversity seeking to promote respect for the letter
and spirit of the Convention.
Discussion
193 governments are Parties to the Convention on Biological
Diversity. Additional countries, notably the United States, are
signatories but have not yet ratified the Convention. The rise of
synthetic biology is of relevance to the three objectives of the
Convention concerning the conservation, sustainable use and fair
and equitable benefit sharing arising from the utilization of genetic
resources. Synthetic biology is also relevant to the protocols
established under the Convention with respect to biosafety,
liability and redress, and access to genetic resources and benefit
sharing. We briefly address each of these areas before considering
proposals for a moratorium on the field release of synthetic
organisms, cells and components.
163 countries are Parties to the Cartagena Protocol on Biosafety
under the Convention that is concerned with regulation, risk
assessment and liability issues for the movement of Living
Modified Organisms (LMOs). Under Article 3(g) of the Cartagena
Protocol a living modified organism ‘‘means any living organism
that possesses a novel combination of genetic material obtained
through the use of modern biotechnology.’’ Article 3(i) defines
modern biotechnology as: ‘‘a) in vitro nucleic acid techniques,
including recombination deoxyribonucleic acid (DNA) and direct
injection of nucleic acid into cells or organelles, or b) Fusion of
cells beyond the taxonomic family that overcome natural
physiological reproductive or recombination barriers and that
are not techniques used in traditional breeding and selection.’’ The
Cartagena Protocol establishes an advanced informed agreement
procedure to provide countries with a basis for making informed
decisions on whether to accept shipments of LMOs meeting the
above criteria.
Figure 9. Journal Subject Categories Core and Citing Landscapes. This figure compares the Thomson Reuters Web of Science journal subject
categories for journal articles in the core landscape (orange) with those in the citing landscape (blue). Data was split on the subject category field to
focus on individual journal subject categories.
doi:10.1371/journal.pone.0034368.g009
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the Nagoya-Kuala Lumpur Supplementary Protocol on Liability
and Redress to the Cartagena Protocol on Biosafety. This protocol
establishes international rules and procedures on liability and
redress relating to living modified organisms. These rules cover
situations involving damage arising from transboundary move-
ments of LMOs intended for direct use as food or feed, for what is
called ‘‘contained use’’ (i.e. in industrial facilities) and intentional
introduction into the environment. The rules also address damage
arising from authorized use of LMOs and unintentional and illegal
transboundary movements.
The provisions of the Cartagena Protocol are likely to lead to
legal questions on whether the products of synthetic biology fall
within the scope of the Cartagena Protocol i.e. do the criteria
apply only to in vitro techniques or approaches involving cell fusion
outside the taxonomic family that overcome natural reproductive
or recombination barriers as set out in the Cartagena Protocol?
Furthermore, it may be that the Cartagena protocol only applies
to the physical transfer of LMOs and does not apply to material or
digital transfers of genetic sequences, components and parts that
may be later used to constitute an LMO [119]. Additional doubts
have also been expressed about whether the waiver on the
requirement for advanced informed agreement for transfers of
LMOs destined for contained use in a facility under Article 6.2 of
the Cartagena protocol should apply in the case of synthetic
organisms [119]. In the case of the Kuala Lumpur supplementary
protocol, this is limited in three ways. First, the rules apply only to
transboundary movements that occur after the supplementary
protocol has entered into force. Second, the rules are restricted to
damage occurring in areas under national jurisdiction (i.e.
excluding the high seas and treaty areas such as Antarctica).
Third, in the case of damage arising from transboundary
Figure 10. Top Funding Organizations. This map shows the network of relations between funding organizations appearing in 5 or more
publications within Web of Science on synthetic biology. The figure was generated using the Force Atlas algorithm and the results were manually
adjusted with the objective of preventing incorrect node to edge intersections. It should be noted that large nodes such as the US National Science
Foundation may display intersections with unrelated edges.
doi:10.1371/journal.pone.0034368.g010
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supplementary protocol then Parties are only able to apply
domestic implementing legislation for the protocol, rather than
seeking redress through an international body.
Synthetic biology is also relevant to the third objective of the
Convention on access to genetic resources and benefit sharing and
the recently concluded Nagoya Protocol on Access to Genetic
Resources and the Fair and Equitable Sharing of Benefits Arising
from their Utilization. Here concerns have been expressed with
regard to the use of artemisinin and the increasing ease with which
genetic material can be transformed into digital information,
transmitted, reproduced and manipulated [119]. Research on
natural product based drug discovery in synthetic biology is closely
linked with metabolic engineering [120] and reviving interest in
compounds from natural products [121] along with the use of
engineered microorganisms for drug development [122,123]. We
have also seen that research in synthetic biology is increasingly
informing wider research in the citing landscape on drug
discovery, antibiotics and vaccines.
We suggest that more detailed empirical analysis of the
implications of synthetic biology for access and benefit sharing is
desirable notably with respect to the source of materials and the
positive or negative economic implications of synthetic biology for
developing countries. Here we note that synthetic biology may
provide cost effective means for drug discovery and development.
Positive outcomes may be possible for developing countries where
drug discovery focuses on neglected diseases. The emerging
involvement of researchers from China, India, Brazil, Mexico and
South Africa in work on synthetic biology may provide positive
opportunities for funding bodies to promote research directed to
the needs of populations in developing countries. As part of this
process funding bodies could also be encouraged by Parties to the
Convention to contribute to the effective implementation of the
Nagoya Protocol on Access to Genetic Resources and Benefit
Sharing as the new international standard governing access and
benefit-sharing for genetic resources across a spectrum of research
fields.
The main focus of debate at SBSTTA and the 11
th Conference
of the Parties to the Convention on Biological Diversity will be the
potential field release of synthetic life, cells or genomes into the
environment taking account of the precautionary principle. In
preparation for this debate a number of civil society organizations,
including the ETC Group, The Center for Food Safety, Econexus,
Friends of the Earth USA, the International Center for
Technology Assessment and the Sustainability Council of New
Zealand have made individual and joint submissions on this topic.
The key recommendation by the International Civil Society
Working Group on Synthetic Biology (ICSWGSB) is that:
‘‘Parties to the Convention on Biological Diversity, in
accordance with the precautionary principle, which is key
when dealing with new and emerging scientific and
technological issues, should ensure that synthetic genetic
parts and living modified organisms produced by synthetic
biology are not released into the environment or approved
for commercial use until there is an adequate scientific basis
on which to justify such activities and due consideration is
given to the associated risks for biological diversity, also
including socio-economic risks and risks to the environment,
human health, livelihoods, culture and traditional knowl-
edge, practices and innovations’’ (ICSWGSB 2011: 5).
These organizations further call upon governments to ‘‘submit
views and national experiences and identify gaps in the
governance of synthetic genetic parts and living modified
organisms produced by synthetic biology as developed for release
or commercial use’’ as a basis for further work under the
Convention (ICSWGSB 2011: 5). In addition they recommend
that countries conduct impact assessments for proposed synthetic
biology projects and that in the absence of reliable data on
biocontainment strategies ‘‘products incorporating such technol-
ogies should not be approved by Parties for field testing…’’ or
commercial use until there is adequate scientific data on their
environmental and socio-economic impacts (ICSWGSB 2011: 6).
If adopted these recommendations would have serious implica-
tions for the conduct of scientific research in synthetic biology.
The first of these recommendations constitutes a call for a
moratorium on the environmental release of synthetic organisms
and synthetic parts and finds a precedent under the Convention in
a 2006 decision to introduce a de facto moratorium on Genetic Use
Restriction Technologies (GURTS or ‘‘Terminator’’ technologies)
(decision VIII/23 C) [124,125]. The specific recommendation on
biocontainment appears to reflect concerns about the scientific
credibility and implications of proposals that synthetic components
or organisms could be engineered to depend on non-natural
amino acids [126], or deploy ‘fail fast’ [127] or suicide mechanisms
to prevent survival in the natural environment [128].
The question of a potential moratorium on synthetic biology as
a field was considered as part of the 2010 United States
Presidential Commission for the Study of Bioethical Issues report
on synthetic biology [8]. In presenting its report the ‘‘PCBSI
concluded that synthetic biology is capable of significant but
limited achievements posing limited risks. Future developments
may raise further objections, but the Commission found no reason
to endorse additional federal regulations or a moratorium on work
in this field at this time. Instead, the Commission urges monitoring
and dialogue between the private and public sectors to achieve
open communication and cooperation’’ (PCBSI 2010: v). In
arriving at this conclusion the Commission sought to find a middle
ground between a moratorium on synthetic biology pending
assessment of all risks and ‘‘unfettered freedom for scientific
exploration’’. The Commission recommended ‘‘an ongoing
process of prudent vigilance that carefully monitors, identifies
and mitigates potential and realized harms over time’’ (PCBSI
2010: 8). With respect to moral objections, the Commission
argued that ‘‘Current objections to synthetic biology on moral
grounds are often based on concerns regarding activities that the
field is currently incapable of carrying out’’ (PCBSI 2010: 12).
However, while rejecting a moratorium on the field as a whole,
the Commission also recognised the potential high risks and
uncertainties around the deliberate release of synthesized organ-
isms and recommended an ongoing review ‘‘of the ability of
synthetic organisms to multiply in the natural environment and
identify, as needed, reliable containment and control mechanisms’’
(PCBSI 2010: 130). In practice, therefore the recommendations
from civil society organizations and the US Presidential Commis-
sion for the Study of Bioethical Issues, as the major government
sponsored review to date, are not incompatible in their main
elements focusing on environmental risk and uncertainty. The
question becomes the appropriate course of action.
In considering synthetic biology a number of choices will be
available to SBSTTA and Parties to the Convention. Thus,
SBSTTA may recommend that greater time is taken to receive
information about synthetic biology and the implications of
potential release of synthetic components and organisms into the
environment before a decision is taken on regulating environmen-
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recommendation to establish a technical expert group to consider
the available evidence and to develop detailed recommendations
for future consideration by the Conference of the Parties.
However, the Conference of the Parties, as the Convention’s
sovereign decision-making body, might decide to introduce a
moratorium on the release of synthetic organisms and components
based on the existing uncertainties and risks to biological diversity.
Such a decision would have major implications for future research
in synthetic biology across the spectrum of research areas in which
synthetic biologists are involved. The implications for synthetic
biologists would need to be balanced against the fundamental
importance of biological diversity to human welfare. The question
in this case would become whether a balance could be identified
which permitted the continued development of synthetic biology
as a field while safeguarding biological diversity.
If a moratorium is regarded as desirable by the Conference of
the Parties, the design of such a moratorium would merit careful
consideration. For example, a moratorium could be designed that
provided opportunities for regular periodic review to allow for the
development and testing of biocontainment and control strategies.
This approach would recognise the presently limited nature of
synthetic biology research directed to field release and the
limitations of existing research on engineered biocontainment
and control strategies. The existence of a moratorium might, as an
incidental benefit, send a strong signal to the ‘biohacking’
community on the acceptable limits of behaviour and encourage
wider professionalisation in a field involving a meeting of different
disciplines and standards. In short, a moratorium could buy time
for the field to develop appropriate standards.
Independent of the question of a moratorium, our research
reveals that targeting funding organizations provides a key
opportunity to promote appropriate governance in synthetic
biology. Specifically, Parties could invite funding organizations
to ensure that research they fund is supportive of, and does not run
counter to, the objectives of the Convention. This is standard
language within the text of the Convention. Such an invitation
would serve to promote greater awareness of the Convention
among public funding bodies and private foundations that
recognise the importance of international commitments on the
environment. Over the longer term more specific guidance could
be developed for funding organizations as understanding of this
field improves.
In the intervening period, Parties to the Convention should be
encouraged to seek further information on synthetic biology
through engagement with the scientific community and be
informed by independent scientific assessment of the actual and
potential risks to biological diversity posed by synthetic biology.
The research presented in this article on the core scientific
landscape for synthetic biology provides a basic platform for
identifying and engaging with the organizations and researchers
involved in synthetic biology and for the development of
transparent monitoring mechanisms to inform decision-making.
Conclusion
This article has aimed to contribute to upcoming debates on
synthetic biology under the United Nations Convention on
Biological Diversity by mapping the scientific landscape for
synthetic biology. Through the exploration of the core landscape
of synthetic biology and its impacts within the wider scientific
literature we have sought to contribute to the creation of a baseline
for wider understanding and engagement with this emerging field.
To achieve this objective we have exploited the increasing
availability of digital tools for visualisation and interaction with
scientific data to promote engagement with this field of research.
Debate under the Convention on Biological Diversity on
synthetic biology is likely to focus on the question of a potential
moratorium on the field release of synthetic organisms, cells and
genomes into the environment. As a contribution to debate on this
issue we have established that the core landscape for synthetic
biology involves 2,934 researchers from 682 organizations in 40
countries who are supported by a network of approximately 530
funding organizations. These researchers are engaged in work on
genetic components, parts and organisms with potential for a wide
range of applications. This community has demonstrated a
considerable willingness to engage with civil society and policy
and to consider appropriate measures for governance. However, at
this early stage in the development of this field proposals regarding
biocontainment and control remain under developed. In consid-
ering the introduction of a possible moratorium on field release
Parties will be confronted by the challenge of balancing the
fundamental importance of biodiversity to human welfare with
recognition of the importance of the ‘‘freedom indispensable for
scientific research and creative activity’’ as set out in Article 15.3 of
the International Covenant on Economic, Social and Cultural
Rights.
In our view, if a moratorium is introduced on field release
opportunities should be provided for periodic review of biocon-
tainment and control measures to encourage further development
in this area. Furthermore, we have argued that important
opportunities exist for introducing appropriate governance
measures through the development of guidance for funding
bodies. Finally, the core contribution of this article has been to
promote the development of longer term monitoring capacity.
Taken together we believe that these proposals can help ensure
that any action taken under the Convention is balanced and
measured and does not unnecessarily impinge on positive
developments in research while remaining attentive to the
significant potential negative impacts of synthetic biology and
the need to ensure they are objectively assessed and addressed.
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